ischemic threshold. 14 patients with CAD and 14 patients with PAOD were randomly assigned either to (ET) or an inactive control group (C). Ergometer and treadmill training was performed 6 times daily for a period of 4 weeks. The concentration of EPCs was analyzed by FACS-analysis of CD34+/KDR+ cells. In cell culture the amount of EPCs was determined by analyzing Di-LDL and FITC-Lectin double positive stained cells using Laser Scanning Cytometry. After 4 weeks of ET crrculating EPCs showed ho srgnificant differences in IP rn comparison to baseline levels (cell culture: 1.6+0.5fold increase ; n.s. vs. baseline and C ; FACS: 1.3*0.3fold increase , n.s. vs. baseline and C). In PAOD patients regular ET leads to a significant increase of EPC during the training period with a peak after 3 weeks (cell culture: 6.2+3.4fold increase ; peO.01 vs. baseline and C ; FACS: 3.2+1.8fold increase , p<O.Ol vs. baseline and C). In conclusion, the present study demonstrates that exercise training in symptomatic CAD patients below the ischemic threshold is Insufficient to induce an increase in the number of circulating EPCs. In contrast treadmill training in PAOD patients beyond the ischemfc threshold seems to be a potent trigger for an EPC release. 
In patients with coronary artery disease (CAD) exercrse training (ET) is regularly associated with a decrease in exercise-induced myocardial ischemia. Recently it has been
shown that a symptom-limited exercrse test is sufhcrent to increase circulating endothslral progenitor cells (EPC) in patients with symptomatrc CAD. Until now, however less IS known about the impact of regular ET on the amount of circulating EPCs. Aim of thus stodv was to investroate the effects of ET on the number of EPCs in oatrents with svfnotomatic CAD. To define the role of ischemia during ET we also analyzed the effect'of treadmill trainino in oatrents with oerioheral arterv occlusive disease iPAODI bevond the _ i, ischemic threshold. 14 patients with CAD and 14 patients with PAOD were randomly assigned either to (ET) or an inactive control group (C). Ergometer and treadmill training was performed 6 times daily for a period of 4 weeks. The concentration of EPCs was analyzed by FACS-analysis of CD34+/KDR+ cells. In cell culture the amount of EPCs was determined by analyzing Di-LDL and FITC-Lectin double positive stained cells using Laser Scanning Cytometry. After 4 weeks of ET crrculating EPCs showed ho srgnificant differences in IP rn comparison to baseline levels (cell culture: 1.6+0.5fold increase ; n.s. vs. baseline and C ; FACS: 1.3*0.3fold increase , n.s. vs. baseline and C). In PAOD patients regular ET leads to a significant increase of EPC during the training period with a peak after 3 weeks (cell culture: 6.2+3.4fold increase ; peO.01 vs. baseline and C ; FACS: 3.2+1.8fold increase , p<O.Ol vs. baseline and C). In conclusion, the present study demonstrates that exercise training in symptomatic CAD patients below the ischemic threshold is Insufficient to induce an increase in the number of circulating EPCs. In contrast treadmill training in PAOD patients beyond the ischemfc threshold seems to be a potent trigger for an EPC release. Background Low serum HDL cholesterol (HDL-C) predicts coronary heart disease (CHD). The Bezafibrate Infarction Prevention (BIP) trial was designed to assess the effcacy of raising HDL-C in CHD patients with HDL-C <45 mg/dL. In this analysis of an extended 8.2-year follow-up of the trial we evaluated the association between HDL-C modification and all-cause and cardiac mortality. Methods Study patients were randomized to receive either bezafibrate 400 mg daily or placebo. The experience of the 1509 bezafibrate treated patients, in tertiles of on-treatment increments in the ratio of HDL-C to total cholesterol (%HDL-C), was compared with that of the 1517 patients in the placebo group, to examine the effect of %HDL-C changes on ail-cause and cardiac mortality.
Results Over a mean follow-up period of 8.2 years the mortality rate was 15.2% in tne placebo group and 13.9% in the bezafibrate group (~~0.33). Bounds for each on-treatment tertile of %HDL-C change were 1 (-4.8% to +2.2%); 2 (+2.2% to +5.1%); and 3 (+5.1% to +19.7%). All-cause mortality rates were 17.3% (n=497), 13.4% (n=514), and 11 .O% (n=498) in tertiles 1, 2 and 3, respectively (p=O.O2). The reduction rn all-cause mortality reflected a highly significant decline in the cardiac mortality rate with increasing increments in %HDL-C (placebo group -8.9 %; tertile 1 -10.9%; tertile 2 5.8%; tertile 3 5.6%; p=O. 
Conclusions
In CHD patients with HDL-C ~45 mg/dL, successful modification of the fraction of total serum cholesterol contained in the HDL moiety with bezafibrate therapy, is independently associated with improved long-term survrval.
9:15 a.m. Methods: EZE coadministered with simvastatin (SIMV) was evaluated in a randomized, double-blind, placebo (PBO)-controlled study in 668 patients with primary hypercholesterolemia. After NCEP diet, a drug washout and 4.wk, single-blind, PBO lead-in period, oatients with baseline LDL-C 2145 to Q50 ma/d1 and TG ST50 ma/d1 were randomized to ; of the following administered daily for 12 consecutive wks: EZE;O mg; SIMV 10, 20,40 or 80 mo: EZE 1Oma + SIMV 10.20.40 or 80ma: or PBO.
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